Zhang Huicong, Zhou Youxia, Song Gang
Department of Respiratory, Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, China.
Department of General Internal Medicine, Shijiazhuang Fourth Hospital, Shijiazhuang, China.
Front Med (Lausanne). 2025 Apr 16;12:1472947. doi: 10.3389/fmed.2025.1472947. eCollection 2025.
Traditional Chinese medicine has been used for the treatment of chronic obstructive pulmonary disease (COPD). However, the effect of Bufei Yishen and Qutan Tongluo Cream (BYQTC) on the amelioration clinical symptoms of COPD remains unclear.
The enrolled COPD patients were randomly divided into control and observation groups. The efficacy of BYQTC was assessed by the reduction rate of syndrome scores. The improvement effect of BYQTC in COPD patients was evaluated using forced expiratory volume in 1 s, 6-minute walk test, modified British Medical Research Council and COPD Assessment Test. The level of serum interleukin 8 (IL-8) and matrix metalloproteinase 9 (MMP-9) was evaluated by enzyme-linked immunosorbent assay.
The observation group had a higher clinical control and effectual rate than the control group. After treatment, the improvement of pulmonary function and movement endurance in the observation group was stronger than that in the control group. Meanwhile, the clinical symptoms of COPD were alleviated more in the observation group. Additionally, the decrease in serum IL-8 and MMP-9 levels in the observation group was higher than that in the control group. Finally, the acute exacerbation and rehospitalization of the COPD patient in the observation group was less than that in the control group.
BYQTC significantly enhances the efficacy of conventional therapy in stable COPD patients, resulting in improvements in clinical symptoms, lung function, and overall quality of life. Notable enhancements were observed in FEV1%, 6MWT distance, and reductions in mMRC and CAT scores. Additionally, BYQTC treatment led to substantial decreases in IL-8 and MMP-9 levels, and reduced the incidence of acute exacerbations and rehospitalizations, demonstrating its superior therapeutic benefit compared to standard treatment.
中医药已用于慢性阻塞性肺疾病（COPD）的治疗。然而，补肺益肾祛痰通络膏（BYQTC）对改善COPD临床症状的效果仍不明确。
将纳入的COPD患者随机分为对照组和观察组。通过证候积分降低率评估BYQTC的疗效。采用第1秒用力呼气容积、6分钟步行试验、改良英国医学研究委员会分级和慢性阻塞性肺疾病评估测试来评价BYQTC对COPD患者的改善效果。采用酶联免疫吸附测定法评估血清白细胞介素8（IL-8）和基质金属蛋白酶9（MMP-9）水平。
观察组的临床控制率和有效率高于对照组。治疗后，观察组肺功能和运动耐力的改善强于对照组。同时，观察组COPD的临床症状缓解更明显。此外，观察组血清IL-8和MMP-9水平的下降高于对照组。最后，观察组COPD患者的急性加重和再住院次数少于对照组。
BYQTC显著提高了常规治疗对稳定期COPD患者的疗效，改善了临床症状、肺功能和整体生活质量。在第1秒用力呼气容积百分比、6分钟步行试验距离方面有显著提高，改良英国医学研究委员会分级和慢性阻塞性肺疾病评估测试得分降低。此外，BYQTC治疗导致IL-8和MMP-9水平大幅下降，降低了急性加重和再住院的发生率，显示出其与标准治疗相比具有更好的治疗效果。
